Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Tissue kallikrein (TK) is present and co-localises with prolactin producing cells in human prolactinoma and mixed growth hormone (GH) and prolactin-secreting pituitary adenomas. TK immunoreactivity was reduced or absent in these types of adenomas from patients who had received the dopamine agonist, bromocriptine before surgery. Pure GH secreting adenomas had no TK immunoreactivity.
Jones
T H
TH
University Department of Medicine, Northern General Hospital, Sheffield, UK.
Figueroa
C D
CD
Smith
C M
CM
Bhoola
K D
KD
D000236:Adenoma / Q000188:drug therapy / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007610:Kallikreins / Q000032:analysis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D011388:Prolactin / Q000378:metabolism*; D015175:Prolactinoma / Q000188:drug therapy / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D020840:Tissue Kallikreins
D001971:Bromocriptine; D011388:Prolactin; D013006:Growth Hormone; D007610:Kallikreins; D020840:Tissue Kallikreins